ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals
Complete the form below to unlock access to ALL audio articles.
ERS Genomics holds rights to foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.
"We are pleased to include Regeneron, a leading biopharmaceutical company, into our portfolio of licensees,” said Shaun Foy, CEO and Founder of ERS Genomics. “Genome editing has many applications in drug discovery and development and making the CRISPR-Cas9 patents widely available to biotechnology and pharmaceutical companies is an important part of ERS Genomics’ strategy."
Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna, (Jinek et al., 2012), which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome-editing tool.
Financial details of the agreement were not disclosed.
